Published in Mol Ther on March 19, 2015
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer | NCT02639234
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma | NCT02574533
Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA) | NCT03495921
Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity. J Clin Med (2016) 0.77
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma. Mol Ther (2016) 0.77
Targeted immunotherapy for pediatric solid tumors. Oncoimmunology (2015) 0.75
Immunotherapies in sarcoma: Updates and future perspectives. World J Clin Oncol (2017) 0.75
The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells. Oncotarget (2016) 0.75
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma. Mol Ther (2016) 0.75
Novel TGF-β inhibitors ready for prime time in onco-immunology. Oncoimmunology (2016) 0.75
Proprotein convertase inhibition: Paralyzing the cell's master switches. Biochem Pharmacol (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol (2006) 9.53
Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer (2006) 8.59
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med (2003) 8.48
Deactivation of macrophages by transforming growth factor-beta. Nature (1988) 5.56
Transforming growth factor-beta: biological function and chemical structure. Science (1986) 5.08
Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest (1992) 4.49
TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell (2005) 4.46
Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol (2000) 4.15
Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev (2005) 4.05
Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta (2006) 3.64
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
The TGF-beta family of growth and differentiation factors. Cell (1987) 2.86
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med (2012) 2.85
Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol (2008) 2.57
Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res (2010) 2.51
Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer (2011) 2.49
Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci (2003) 2.36
Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol (2005) 2.33
Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene (2001) 2.27
TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol (1999) 2.05
Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol (1989) 1.79
Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer (2002) 1.60
TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells. J Immunol (1998) 1.59
Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol (2003) 1.43
Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol (1988) 1.33
Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A (1996) 1.30
High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol (2001) 1.23
Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol (2010) 1.22
Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells (1997) 1.21
Bidirectional regulation of macrophage function by TGF-beta. Microbes Infect (1999) 1.20
The role of transforming growth factor beta in glioma progression. J Neurooncol (1998) 1.17
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther (2011) 1.15
Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution. Sarcoma (2006) 1.11
Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol (2009) 1.09
A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res (2008) 1.08
The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer (2012) 1.06
The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg (1993) 1.04
Mechanism of inhibition of LPS-induced IL-12p40 production by IL-10 and TGF-beta in ANA-1 cells. J Leukoc Biol (1998) 1.03
Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1. Br J Cancer (1994) 1.02
Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther (2008) 0.99
Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res (2011) 0.99
Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother (1993) 0.97
Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells. Br J Cancer (2011) 0.91
Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res (1998) 0.90
Multimodal therapy for the treatment of nonmetastatic Ewing sarcoma of pelvis. J Pediatr Hematol Oncol (2003) 0.90
The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer (2014) 0.88
Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. Br J Cancer (2013) 0.88
Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors. J Surg Oncol (2010) 0.86
EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors. Clin Cancer Res (2012) 0.84
Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor. Cancer Immunol Immunother (1991) 0.83
TGF beta 1 and TGF beta 2 are potential growth regulators for medulloblastomas, primitive neuroectodermal tumors, and ependymomas: evidence in support of an autocrine hypothesis. Hum Pathol (1994) 0.83
Round cell sarcomas - biologically important refinements in subclassification. Int J Biochem Cell Biol (2014) 0.83
Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells. Neurol Med Chir (Tokyo) (1996) 0.82
Characterization of Ewing sarcoma associated cancer/testis antigens. Cancer Biol Ther (2013) 0.81
Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model. J Neuroimmunol (1998) 0.81
Multifunctional vaccines in cancer: the 'triad' approach. Expert Rev Vaccines (2011) 0.80
Amyloid precursor-like protein 2 suppresses irradiation-induced apoptosis in Ewing sarcoma cells and is elevated in immune-evasive Ewing sarcoma cells. Cancer Biol Ther (2013) 0.79
TGF-B2 and soluble p55 TNFR modulate VCAM-1 expression in glioma cells and brain derived endothelial cells. J Neuroimmunol (1997) 0.78
Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas. BMC Clin Pathol (2012) 0.76
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma. Mol Ther (2016) 0.77
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer. Mol Ther (2015) 0.76
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma. Mol Ther (2016) 0.76
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma. Mol Ther (2016) 0.75
Phase I Trial of "bi-shRNAi(furin)/GMCSF DNA/Autologous Tumor Cell" Vaccine (FANG) in Advanced Cancer. Mol Ther (2016) 0.75